VCEL / Vericel: Aggressive Growth In 2023

Vericel Corporation demonstrates consistent growth in its core product lines, including MACI for cartilage repair and Epicel for severe burn treatment more_horizontal

Vericel Corporation (VCEL) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to more_horizontal

CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and sev more_horizontal

The FDA's recent approval of NexoBrid for the treatment of burns is expected to drive revenue growth in 2023. Vericel's MACI autologous cell therapy p more_horizontal

Vericel Corporation (NASDAQ:VCEL ) Q4 2022 Earnings Conference Call February 23, 2023 8:30 AM ET Company Participants Eric Burns – Head-Financial Pl more_horizontal

Vericel Corporation (VCEL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estima more_horizontal

CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and seve more_horizontal

Various ongoing fundamental improvements signal significant upsides. The recent NexoBrid approval foretells leaping sales growth in the coming quarter more_horizontal